|New Threads Only:|
|New Threads & Replies:|
Forum List » Value Ideas and Strategies|
Share and discuss value investing ideas and investing strategies.
Drug Penny Stock
Posted by: DanielS (IP Logged)
Date: August 23, 2011 07:59AM
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases.
The company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a range of therapeutic areas.
The company currently has seven wholly owned programs in its development pipeline: ARRY-403, a glucokinase activator for Type 2 diabetes; ARRY-162, a MEK inhibitor for rheumatoid arthritis and cancer; ARRY-380, an ErbB-2 inhibitor for breast cancer; ARRY-520, a KSP inhibitor for acute myeloid leukemia and multiple myeloma; ARRY-614, a p38/Tie 2 dual inhibitor for myelodysplastic syndrome; ARRY-543, an ErbB family (ErbB-2 / EGFR) inhibitor for solid tumors; ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications.
The company's drug discovery efforts have also generated additional early-stage drug candidates that it might choose to out-license through research partnerships prior to filing an IND application.
The company's drug discovery programs include an inhibitor that targets the kinase Chk-1 for the treatment of cancer and an inhibitor that targets a family of tyrosine kinase, or Trk, receptors for the treatment of pain. Its Chk-1 inhibitor is a first-in-class, selective, oral drug candidate and in preclinical studies has shown prolonged inhibition of the Chk-1 target. The Company's Trk family inhibitor is a first-in-class, selective, oral drug candidate targeting Trk A, B, and C.
The company has collaborations with pharmaceutical and biotechnology companies under which it has out-licensed certain of its proprietary drug programs for further research, development and commercialization.
The company also has research partnerships with pharmaceutical and biotechnology companies, for which it designs, creates and optimizes drug candidates, and conduct preclinical testing across a range of therapeutic areas, on targets selected by its partners.
The company competes with companies worldwide that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations.
The company is subject to substantial regulation by governmental agencies in the U.S. and other countries.
The company ended its 2011 fiscal year on June 30, 2011, with $91.4 million in long-term debt, which was reduced by 19% from $112.8 million one year ago. As of Aug. 5, 2011, reported 57 million shares of common stock outstanding and cash and cash equivalents of $65.
The company announced a corporate restructuring that included a 20% staff reduction to reduce its projected cash burn rate for FY12 (which ends June 30, 2012) by $20 million to an estimated level of $40 million – compared to cash and cash equivalents of $93 million. The company is in a strong financial position thanks to the corporate restructuring to reduce the cash burn rate.
Let´s check charts:
It is a weekly chart since 2006. It is looks like a very good opportunity to buy and hold. The stop is in 1.70, and the target is 8.
Trade safe. Trade well.
Stocks Discussed: ARRY,
Posted by: ry.zamora (IP Logged)
Date: August 29, 2011 07:47PM
Well, I visited Google Finance, and went straight to ARRY's annual financials.
It speaks to me as a speculative investment rather than value.
Operating income has been negative for the past four years, swallowed up by very high R&D costs. Assets rely on LT debt as a crutch, especially in light of negative equity. Then there's operating cash flows being negative in all four years if you chose to ignore working cap changes.
As far as the financials are concerned, ARRY is more likely to be a value trap than an actual bargain. Investors who'd buy the company are more interested in favorable developments regarding its research. Now, the data I unearthed from Array's website regarding ARRY-403 (Type 2 diabetes), ARRY-162 (rheumatoid arthritis, cancer), ARRY-380 (breast cancer), ARRY-520 (leukemia, multiple myeloma), ARRY-614 (myelodysplastic syndrome), ARRY-543 (tumors), and ARRY-797 (cancer supportive care, subacute pain), have all shown positive signs in the past two years alone... which are all great news.
However, consider that some are clinical trials, and others haven't even gone on to evaluations with human volunteers. We have no idea how strict the FDA may be towards ARRY, and we certainly have no idea how long would be the payback period of these pharmaceutical products. Unknown variables are still prevalent, and this all points to a speculative nature. The short time I spent conducting research on ARRY did not focus on the company's competitors, so I don't even have any information on just how far those adversaries have gone.
ARRY-162: shown significant antitumor activities in preclinical studies (cell lines and animal models), and currently in Phase I trials with solid tumors (source: Novartis Oncology). Abstract from Array (PDF file) indicates favorable clinical results with the drug.
ARRY-403: abstract #361 informs us that drug is highly efficacious and safe in preclinical models. Was orally administered to 41 volunteers with Type 2 diabetes. Conclusions of data say drug is well-tolerated (no serious adverse reactions), and significantly reduced post-meal and 24-hour fasted blood glucose. Has "potential" for first line therapy in patients with Type 2 diabetes.
ARRY-380: An April 2011 presentation by Kevin Koch updates that this drug is currently undergoing Phase 1 expansion. Slide 20 informs us that drug shrunk tumors in 51% of the HER2+ volunteers. Confirmed partial responses (slide 21) shows 100% tumor shrinkage.
Summary on slide 28 says it is potent and administered orally. Drug has favorable clinical PK, with low frequency and intensity of adverse reactions. Effective in "mono-therapy" and in combination.
ARRY-520: April 2011 PDF abstract tells us drug has "potent antitumor activity as a single agent", but document only admits that results provide merely a rationale for clinical evaluation. Testing is obviously still in progress.
ARRY-614: a 2009 PDF abstract summarizes preclinical studies by saying it is effective in inhibiting cytokine production in multiple cell types, and in inhibiting multiple myeloma xenograft alone. It is well-tolerated, and has entered clinical trials two years ago. Array does not provide any additional documents following the abstract when a search for ARRY-614 is run through its systems.
ARRY-543: no data later than 2008. Data in 2008 PDF abstract suggest potential to be a clinically active drug. Website's short snippet of the drug says it "showed promising results in preclinical tumor models that signal through multiple HER family members, as well as in preclinical models when compared to, and combined with, Herceptin (trastuzumab), Xeloda (capecitabine) and Taxotere (docetaxel) – widely used treatments for solid tumors." (url right here)
ARRY-797: 2010 document shows it has undergone clinical evaluation. Summary informs readers drug is proven safe and well-tolerated. In all clinical studies, 371 patients were given doses, and adverse reactions ranged from mild to moderate. Drug has shown signs of "acute and durable" analgesic properties in the studies.
Stocks Discussed: ARRY,
Re: Drug Penny Stock
Posted by: MichaelFrayn (IP Logged)
Date: November 8, 2011 07:28AM
It is looks like a very good opportunity to buy and hold.
Penny stocks require even greater attention than other stocks, which require at least daily attention.
Stocks Discussed: ARRY,
Re: Drug Penny Stock
Posted by: JamesBalfour (IP Logged)
Date: November 11, 2011 06:36AM
I think stock market is the way to invest money. There are many agencies best online stock trading that will help people to invest in the stock market.
Stocks Discussed: ARRY,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.